| Heterogeneity of genomic evolution and mutational profiles in multiple myeloma N Bolli, H Avet-Loiseau, DC Wedge, P Van Loo, LB Alexandrov, ... Nature communications 5 (1), 2997, 2014 | 1023 | 2014 |
| A small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance D Chauhan, Z Tian, B Nicholson, KGS Kumar, B Zhou, R Carrasco, ... Cancer cell 22 (3), 345-358, 2012 | 606 | 2012 |
| Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma M Fulciniti, P Tassone, T Hideshima, S Vallet, P Nanjappa, SA Ettenberg, ... Blood, The Journal of the American Society of Hematology 114 (2), 371-379, 2009 | 483 | 2009 |
| A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis BA Walker, K Mavrommatis, CP Wardell, TC Ashby, M Bauer, F Davies, ... Leukemia 33 (1), 159-170, 2019 | 473 | 2019 |
| Blockade of XBP1 splicing by inhibition of IRE1α is a promising therapeutic option in multiple myeloma N Mimura, M Fulciniti, G Gorgun, YT Tai, D Cirstea, L Santo, Y Hu, ... Blood, The Journal of the American Society of Hematology 119 (24), 5772-5781, 2012 | 468 | 2012 |
| Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma BA Walker, K Mavrommatis, CP Wardell, TC Ashby, M Bauer, FE Davies, ... Blood, The Journal of the American Society of Hematology 132 (6), 587-597, 2018 | 461 | 2018 |
| HLA class I, NKG2D, and natural cytotoxicity receptors regulate multiple myeloma cell recognition by natural killer cells E Carbone, P Neri, M Mesuraca, MT Fulciniti, T Otsuki, D Pende, V Groh, ... Blood 105 (1), 251-258, 2005 | 430 | 2005 |
| Elevated IL-17 produced by Th17 cells promotes myeloma cell growth and inhibits immune function in multiple myeloma RH Prabhala, D Pelluru, M Fulciniti, HK Prabhala, P Nanjappa, W Song, ... Blood, The Journal of the American Society of Hematology 115 (26), 5385-5392, 2010 | 417 | 2010 |
| Triplet therapy, transplantation, and maintenance until progression in myeloma PG Richardson, SJ Jacobus, EA Weller, H Hassoun, S Lonial, NS Raje, ... New England Journal of Medicine 387 (2), 132-147, 2022 | 355 | 2022 |
| Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease S Vallet, S Mukherjee, N Vaghela, T Hideshima, M Fulciniti, S Pozzi, ... Proceedings of the National Academy of Sciences 107 (11), 5124-5129, 2010 | 313 | 2010 |
| Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma MK Samur, M Fulciniti, A Aktas Samur, AH Bazarbachi, YT Tai, ... Nature communications 12 (1), 868, 2021 | 311 | 2021 |
| Pharmacologic targeting of a stem/progenitor population in vivo is associated with enhanced bone regeneration in mice S Mukherjee, N Raje, JA Schoonmaker, JC Liu, T Hideshima, MN Wein, ... The Journal of clinical investigation 118 (2), 491-504, 2008 | 293 | 2008 |
| Targeted disruption of the BCL9/β-catenin complex inhibits oncogenic Wnt signaling K Takada, D Zhu, GH Bird, K Sukhdeo, JJ Zhao, M Mani, M Lemieux, ... Science translational medicine 4 (148), 148ra117-148ra117, 2012 | 284 | 2012 |
| Genomic landscape and chronological reconstruction of driver events in multiple myeloma F Maura, N Bolli, N Angelopoulos, KJ Dawson, D Leongamornlert, ... Nature communications 10 (1), 3835, 2019 | 283 | 2019 |
| PI3K/p110δ is a novel therapeutic target in multiple myeloma H Ikeda, T Hideshima, M Fulciniti, G Perrone, N Miura, H Yasui, Y Okawa, ... Blood, The Journal of the American Society of Hematology 116 (9), 1460-1468, 2010 | 276 | 2010 |
| The monoclonal antibody nBT062 conjugated to cytotoxic Maytansinoids has selective cytotoxicity against CD138-positive multiple myeloma cells in vitro and in vivo H Ikeda, T Hideshima, M Fulciniti, RJ Lutz, H Yasui, Y Okawa, T Kiziltepe, ... Clinical Cancer Research 15 (12), 4028-4037, 2009 | 250 | 2009 |
| Drugging the lncRNA MALAT1 via LNA gapmeR ASO inhibits gene expression of proteasome subunits and triggers anti-multiple myeloma activity N Amodio, MA Stamato, G Juli, E Morelli, M Fulciniti, M Manzoni, E Taiana, ... Leukemia 32 (9), 1948-1957, 2018 | 240 | 2018 |
| Enhancer invasion shapes MYCN-dependent transcriptional amplification in neuroblastoma R Zeid, MA Lawlor, E Poon, JM Reyes, M Fulciniti, MA Lopez, TG Scott, ... Nature genetics 50 (4), 515-523, 2018 | 224 | 2018 |
| Genomic patterns of progression in smoldering multiple myeloma N Bolli, F Maura, S Minvielle, D Gloznik, R Szalat, A Fullam, ... Nature communications 9 (1), 3363, 2018 | 209 | 2018 |
| Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma YT Tai, BY Chang, SY Kong, M Fulciniti, G Yang, Y Calle, Y Hu, J Lin, ... Blood, The Journal of the American Society of Hematology 120 (9), 1877-1887, 2012 | 205 | 2012 |
Pierfrancesco TassoneProfessor of Medical Oncology, Magna Graecia University, Catanzaro, ItalyEmail được xác minh tại unicz.it